病毒与抗心肌抗体在围生期心肌病发病中的作用

文建平; 汪朝晖; 廖玉华; 袁璟

doi:10.13201/j.issn.1001-1439.2018.09.014

病毒与抗心肌抗体在围生期心肌病发病中的作用

- 1 厦门医学院附属第二医院职业病干部病房(福建厦门, 361021);
- 2 华中科技大学同济医学院附属协和医院心血管内科
基金项目:
厦门医学院校内课题自然科学类 (No:K2017-01)

详细信息

通讯作者: 汪朝晖,E-mail:wuxiaohongtian@163.com

中图分类号: R714.7；R542.2

收稿日期: 2018-03-28

The role of virus and anti-heart antibodies in the pathogenesis of peripartum cardiomyopathy

- 1 Cadre Wards, the Second Hospital of Xiamen, Xiamen, Fujian, 361021, China;
- 2 Institute of Cardiology, Union Hospital, Huazhong University of Science and Technology

More Information

Corresponding author: WANG Zhaohui, E-mail: wuxiaohongtian@163.com

Received Date: 28 March 2018

摘要

摘要: 目的:通过研究围生期心肌病 (PPCM) 患者的病因, 探讨病毒与抗心肌抗体 (AHA) 在PPCM发病中的作用。方法:收集2010-03-2016-03在我院住院确诊为PPCM的女性患者32例, 平均年龄 (27.6±4.4) 岁;其中NYHA心功能分级Ⅲ级者12例 (37.5%)、Ⅳ级15例 (46.8%)。采用逆转录聚合酶链式反应法 (RT-PCR) 检测以下病毒:柯萨奇病毒 (CoxB-IgM)、埃可肠病毒 (EVs-RNA)、巨细胞病毒 (CMV-IgM);以酶联免疫吸附测定 (ELISA) 法检测血清AHA:抗心肌线粒体腺嘌呤核苷酸异位酶 (ANT) 抗体, 抗β1-肾上腺素受体 (β1-AR) 抗体, 抗M2-胆碱能受体 (M2R) 抗体, 抗肌球蛋白重链 (MHC) 抗体;同时对患者病史、诊治过程、随访结果进行回顾性分析。结果:病毒检测为阳性者共22例 (68.7%), 其中CoxB-IgM阳性21例 (65.6%)、EVs-RNA阳性19例 (59.4%)、CMV-IgM阳性12例 (37.5%)。AHA为阳性者共17例 (53.1%), 其中抗ANT抗体阳性15例 (46.8%)、抗β1-AR阳性15例 (46.8%)、抗M2R抗体阳性13例 (40.6%)、抗MHC抗体阳性13例 (40.6%)。病毒与AHA均阳性17例 (53.1%)。32例患者中有高龄产妇9例 (28.1%), 经产妇13例 (40.6%);经抗心力衰竭等治疗后28例 (87.5%) 患者获好转, NYHA分级改善Ⅰ^Ⅱ级。平均随访 (26.7±12.4) 个月, 2例患者死亡。结论:病毒与AHA可能在PPCM的发病中起重要作用。
- 围生期心肌病 /
- 病毒 /
- 抗心肌抗体 /
- 发病
Abstract: Objective: To clear the role of virus and anti-heart antibodies (AHA) in the pathogenesis of peripartum cardiomyopathy (PPCM) by analyzing the cause of this disease.Method: The clinical symptoms, results of laboratory examination, and prognosis of 32 female patients diagnosed of PPCM in our Hospital from March 2010 to March 2016 were studied, with the mean age of (27.6±4.4) years and NYHA with class Ⅲ in 12 patients (37.5%), class Ⅳ in 15 patients (46.8%).Coxasackie B virus (CoxB-IgM), Enteric virus ribonucleic acid (EvsRNA), cytomegalo virus (CMV-IgM) were detected by retrovirus transcription-polymerase chain reaction (RTPCR).The ani-heart antibodies (AHA), including anti-adenine nucleotide translocator (ANT) antibody, anti-β1-adrenocepter (β1-AR) antibody, anti-M2 muscarinic receptor (M2 R) antibody, and anti-myosin heavy chain (MHC) antibody are tested by Enzyme-linked immunoadsordent assay (ELISA).Result: Virus were detected in 22 of 32 (68.7%) patients, including CoxB-IgM (n=21, 65.6%), EVs-RNA (n=19, 59.4%), CMV-IgM (n=12, 37.5%).AHA were investigated in 17 of 32 (53.1%) patients including anti-ANT antibody in 15 (46.8%) patients, anti-β1-AR antibody in 15 (46.8%) patients, anti-M2 R antibody in 13 (40.6%) patients, and anti-MHC antibody in 13 (40.6%) patients.Both of virus and AHA were detected positive in 17 of 32 (53.1%) patients.Other causes included the old age during pregnancy (n=9, 28.1%), and multiple prior pregnancies (n=13, 40.6%) in spite of virus and AHA.After medical therapy for heart failure, the cardiac function of 28 (87.5%) patients improved as measured by NYHA classification.2 (6.3%) patients died at a follow up of (26.7±12.4) months.Conclusion: Virus and AHA might play an important role in the pathogenesis of PPCM.
- peripartum cardiomyopathy /
- Virus /
- anti-heart antibodies /
- pathogenesis

HTML全文

参考文献(13)

[1]	Ersboll AS, Damm P, Gustafsson F, et al.Peripartum cardiomyopathy:a systematic literature review[J].Acta Obstet Gynecol Scand, 2016, 95 (11):1205-1219.
[2]	张丽娟, 陈奕.围生期心肌病的病因学研究进展[J].中国医药导报, 2014, 11 (17):163-166, 169.
[3]	Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al.Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy:a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy[J].Eur J Heart Fail, 2010, 12 (8):767-778.
[4]	颜小飞, 梁薇, 余淼, 等.一种抗心肌抗体检测试剂盒的验证评价[J].临床心血管病杂志, 2015, 31 (2):125-128.
[5]	Fett JD.Peripartum cardiomyopathy:challenges in diagnosis and management[J].Expert Rev Cardiovasc Ther, 2016, 14 (9):1035-1041.
[6]	Hilfiker-Kleiner D, Sliwa K.Pathophysiology and epidemiology of peripartum cardiomyopathy[J].Nat Rev Cardiol, 2014, 11 (6):364-370.
[7]	Hilflker-kleiner D, Haghikia A, Nonhoff J, et al.Peripartum cardiomyopathy:current management and future perspectives[J].Eur Heart J, 2015, 36 (18):1090-1097.
[8]	陈曙霞, 石迪明, 徐瑾, 等.原位PCR法对围生期心肌病柯萨奇B组病毒的检测[J].临床心血管病杂志, 2001, 17 (3):101-103.
[9]	Selle T, Renger I, Labidi S, et al.Reviewing periparum cardiomyopathy:current state of knowledge[J].Future Cardiol, 2009, 5 (2):175-189.
[10]	汪朝晖, 廖玉华.注重心肌病病因学诊断和治疗[J].临床心血管病杂志, 2007, 23 (7):481-483.
[11]	袁璟, 汪朝晖, 廖玉华.从病毒性心肌炎演变为扩张型心肌病:病毒的作用[J].临床心血管病杂志, 2012, 28 (2):81-82.
[12]	袁璟, 廖玉华.抗心肌抗体对心肌炎心肌病临床诊断、治疗和预后评估的价值[J].临床心血管病杂志, 2015, 31 (2):115-118.
[13]	中华医学会心血管病分会, 中华心血管病杂志编委会, 中国心肌病诊断与治疗建议工作组.心肌病诊断与治疗建议[J].中华心血管病杂志, 2007, 35 (1):3-16.